Comparison between Datasol IPO and Goldline Pharmaceutical IPO.
Datasol IPO is a SME Bookbuilding IPO proposed to list at BSE SME while Goldline Pharmaceutical IPO is a SME Bookbuilding proposed to list at BSE SME.
The total issue size of Datasol IPO is up to ₹0.00 Cr whereas the issue size of the Goldline Pharmaceutical IPO is up to ₹0.00 Cr. The final issue price of Datasol IPO is and of Goldline Pharmaceutical IPO is .
| Datasol IPO | Goldline Pharmaceutical IPO | |
|---|---|---|
| Face Value | ₹10 per share | ₹10 per share |
| Issue Price (Lower) | ||
| Issue Price (Upper) | ||
| Issue Price (Final) | ||
| Discount (Retail) | ||
| Discount (Employee) | ||
| Market Lot Size | ||
| Fresh Issue Size | 39,20,000 shares | 30,00,000 shares |
| Fresh Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| OFS Issue Size | 0 shares | 0 shares |
| OFS Issue Size (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
| Issue Size Total | 39,20,000 shares | 30,00,000 shares |
| Issue Size Total (Amount) | up to ₹0.00 Cr | up to ₹0.00 Cr |
Datasol IPO opens on , while Goldline Pharmaceutical IPO opens on . The closing date of Datasol IPO and Goldline Pharmaceutical IPO is , and , respectively.
Datasol IPO P/E ratio is , as compared to Goldline Pharmaceutical IPO P/E ratio of .
| Datasol IPO | Goldline Pharmaceutical IPO | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Financials | Company Financials (Restated)Datasol (Bangalore) Ltd.'s revenue increased by 28% and profit after tax (PAT) rose by 45% between the financial year ending with March 31, 2025 and March 31, 2024.
| Company Financials (Restated)Goldline Pharmaceutical Ltd.'s revenue increased by 19% and profit after tax (PAT) rose by 57% between the financial year ending with March 31, 2025 and March 31, 2024.
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Pre-Issue) | 90 | 79.70 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Promoter Shareholding (Post-Issue) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| P/E Ratio | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Market Cap | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROE | 21.68 | 35.84 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ROCE | 27.55 | 38.46 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Debt/Equity | 0.03 | 1.50 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| EPS | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| RoNW | 19.56 | 27.38 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
In the Datasol IPO Retail Individual Investors (RII) are offered 0 shares while in Goldline Pharmaceutical IPO retail investors are offered 0 shares. Qualified Institutional Buyers (QIB) are offered 0 shares in Datasol IPO and 0 shares in Goldline Pharmaceutical IPO.
| Datasol IPO | Goldline Pharmaceutical IPO | |
|---|---|---|
| Anchor Investor Reservation | 0 shares | 0 shares |
| Market Maker Reservation | 0 shares | 0 shares |
| QIB | 0 shares | 0 shares |
| NII | 0 shares | 0 shares |
| RII | 0 shares | 0 shares |
| Employee | 0 shares | 0 shares |
| Others | ||
| Total | 0 shares | 0 shares |
Datasol IPO subscribed in total, whereas Goldline Pharmaceutical IPO subscribed .
